Literature DB >> 8147452

Anxiogenic effects of CO2 and hyperventilation in patients with panic disorder.

J M Gorman1, L A Papp, J D Coplan, J M Martinez, S Lennon, R R Goetz, D Ross, D F Klein.   

Abstract

OBJECTIVE: Previous studies have indicated that patients with panic disorder are more likely than normal subjects to have acute panic attacks during inhalation of CO2, but methodological objections have been raised. In this study the authors attempted to address three of these methodological problems by ensuring that raters who assessed whether panic attacks occurred were blind to subjects' diagnoses, by randomizing the order of administration of 5% CO2 and hyperventilation, and by challenging a greater number of subjects with 7% CO2.
METHOD: Patients with panic disorder and normal subjects underwent 20-minute inhalations of 5% CO2 and 7% CO2 and 15 minutes of room-air hyperventilation. Ratings of panic/no panic during each condition were made separately by an assessor blind to diagnosis and by the subject. Scores on four panic rating scales were also recorded before and after each intervention.
RESULTS: Room-air hyperventilation caused panic attacks in a small number of patients; the difference in panic rate between patients and comparison subjects was statistically significant by the subjects' but not by the raters' assessment. Panic rates during 5% CO2 and 7% CO2 were significantly greater among the patients by both assessments; the panic rate was greatest during 7% CO2. Order of administration did not significantly affect panic rates for hyperventilation and 5% CO2.
CONCLUSIONS: Panic patients were clearly more sensitive to the anxiogenic effects of CO2 than comparison subjects, and CO2 was a more potent anxiogenic stimulus than room-air hyperventilation. Seven percent CO2 discriminated best between patients and comparison subjects and should be the focus of further research.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8147452     DOI: 10.1176/ajp.151.4.547

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  28 in total

1.  Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325.

Authors:  M Iijima; T Yoshimizu; T Shimazaki; K Tokugawa; K Fukumoto; S Kurosu; T Kuwada; Y Sekiguchi; S Chaki
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

Review 2.  Coping skills and exposure therapy in panic disorder and agoraphobia: latest advances and future directions.

Authors:  Alicia E Meuret; Kate B Wolitzky-Taylor; Michael P Twohig; Michelle G Craske
Journal:  Behav Ther       Date:  2011-08-27

Review 3.  Orexin, stress, and anxiety/panic states.

Authors:  Philip L Johnson; Andrei Molosh; Stephanie D Fitz; William A Truitt; Anantha Shekhar
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

Review 4.  Interoception and learning: import to understanding and treating diseases and psychopathologies.

Authors:  Rick A Bevins; Joyce Besheer
Journal:  ACS Chem Neurosci       Date:  2014-07-22       Impact factor: 4.418

5.  Evaluating the risks of clinical research: direct comparative analysis.

Authors:  Annette Rid; Emily Abdoler; Roxann Roberson-Nay; Daniel S Pine; David Wendler
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-09       Impact factor: 2.576

Review 6.  Hyperventilation in panic disorder and asthma: empirical evidence and clinical strategies.

Authors:  Alicia E Meuret; Thomas Ritz
Journal:  Int J Psychophysiol       Date:  2010-05-25       Impact factor: 2.997

7.  The Effects of Hyper- and Hypocapnia on Phonatory Laryngeal Airway Resistance in Women.

Authors:  Amanda I Gillespie; William Slivka; Charles W Atwood; Katherine Verdolini Abbott
Journal:  J Speech Lang Hear Res       Date:  2015-06       Impact factor: 2.297

8.  [Prevalence of obstructive sleep apnea syndrome (OSA) in patients with sudden hearing loss. A pilot study].

Authors:  Y Fischer; A Yakinthou; W J Mann
Journal:  HNO       Date:  2003-04-15       Impact factor: 1.284

9.  Group II metabotropic glutamate receptor type 2 allosteric potentiators prevent sodium lactate-induced panic-like response in panic-vulnerable rats.

Authors:  Philip L Johnson; Stephanie D Fitz; Eric A Engleman; Kjell A Svensson; Jeffrey M Schkeryantz; Anantha Shekhar
Journal:  J Psychopharmacol       Date:  2012-08-21       Impact factor: 4.153

10.  A key role for orexin in panic anxiety.

Authors:  Philip L Johnson; William Truitt; Stephanie D Fitz; Pamela E Minick; Amy Dietrich; Sonal Sanghani; Lil Träskman-Bendz; Andrew W Goddard; Lena Brundin; Anantha Shekhar
Journal:  Nat Med       Date:  2009-12-27       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.